Safety Profile
Information not yet available for this ingredient profile.
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Burdock root extract is used for detoxification and skin health support. It is generally well tolerated at standard doses. It belongs to the Asteraceae family and may cause allergic reactions in individuals sensitive to ragweed, daisies, or chrysanthemums. It has mild diuretic properties that may interact with diuretic medications. Some traditional preparations have been adulterated with belladonna, causing toxicity. Use from reputable, tested sources only.
Biological and Chemical Classification
- Scientific Name
- Arctium lappa
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- No significant safety signals identified in the reviewed literature.
The available scientific evidence for Burdock Root Extract indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 26 მარ 2026, 14:06
Evidence Distribution
-
Observational / other LOW evidence YELLOWArctiin targets oxidative stress and inflammation, restores Neuregulin-1, and improves neurobehavioral outcomes in neonatal hypoxic-ischemic brain injury. ↗Babak S et al.. Arctiin targets oxidative stress and inflammation, restores Neuregulin-1, and improves neurobehavioral outcomes in neonatal hypoxic-ischemic brain injury.. Curr Res Pharmacol Drug Discov. 2026. PMID:41768550.PMID 41768550 ↗Journal Curr Res Pharmacol Drug DiscovYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41768550/
-
Observational / other LOW evidence YELLOWEffects of Arctium lappa L. Root Powder on Some Markers of Oxidative Stress and Inflammation in Women with Polycystic Ovary Syndrome: A… ↗Taheri H et al.. Effects of Arctium lappa L. Root Powder on Some Markers of Oxidative Stress and Inflammation in Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind Controlled Clinical Trial Study.. JBRA Assist Reprod. 2026. PMID:41757842.PMID 41757842 ↗Journal JBRA Assist ReprodYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41757842/
-
Observational / other LOW evidence YELLOWUnveiling the Antihyperglycemic Potential of Arctium lappa L. (Asteraceae): Traditional Application, Phytochemistry, and Molecular Insights. ↗Uzbekova AA et al.. Unveiling the Antihyperglycemic Potential of Arctium lappa L. (Asteraceae): Traditional Application, Phytochemistry, and Molecular Insights.. Foods. 2026. PMID:41750986.PMID 41750986 ↗Journal FoodsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41750986/
-
Observational / other LOW evidence YELLOWAssembly and Characterization of the First Complete Mitochondrial Genome of Tussilago farfara L.: Insights into Biological Functions and Phylogenetic Relationships within the… ↗Zhang Y et al.. Assembly and Characterization of the First Complete Mitochondrial Genome of Tussilago farfara L.: Insights into Biological Functions and Phylogenetic Relationships within the Asteraceae Family.. Biochem Genet. 2026. PMID:41746552.PMID 41746552 ↗Journal Biochem GenetYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41746552/
-
Observational / other LOW evidence YELLOWBioaccessibility, composition, and anti-inflammtory activity of bound polyphenols from burdock (Arctium lappa L.) root insoluble dietary fiber. ↗Cui J et al.. Bioaccessibility, composition, and anti-inflammtory activity of bound polyphenols from burdock (Arctium lappa L.) root insoluble dietary fiber.. Food Sci Biotechnol. 2026. PMID:41695821.PMID 41695821 ↗Journal Food Sci BiotechnolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41695821/
-
Observational / other LOW evidence YELLOWArctigenin ameliorates neointima formation induced by vascular injury by inhibiting inflammatory response and proliferation through the IL-6/JAK2/STAT3 pathway. ↗Zhao C et al.. Arctigenin ameliorates neointima formation induced by vascular injury by inhibiting inflammatory response and proliferation through the IL-6/JAK2/STAT3 pathway.. Mol Cell Biochem. 2026. PMID:41511720.PMID 41511720 ↗Journal Mol Cell BiochemYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41511720/
-
Observational / other LOW evidence YELLOWAnthelmintic Activity of Traditional Medicinal Plants Used in Europe. ↗Boyko O et al.. Anthelmintic Activity of Traditional Medicinal Plants Used in Europe.. Biology (Basel). 2025. PMID:41463411.PMID 41463411 ↗Journal Biology (Basel)Year 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41463411/
-
Observational / other LOW evidence YELLOWArctium lappa L. Leaves Alleviate Alzheimer's Disease-Like Pathologies by Modulating the Tricarboxylic Acid Cycle and Inhibiting STAT3/NF-u043aB Signaling. ↗Zhang R et al.. Arctium lappa L. Leaves Alleviate Alzheimer's Disease-Like Pathologies by Modulating the Tricarboxylic Acid Cycle and Inhibiting STAT3/NF-u043aB Signaling.. Plant Foods Hum Nutr. 2025. PMID:41417181.PMID 41417181 ↗Journal Plant Foods Hum NutrYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41417181/
-
Observational / other LOW evidence YELLOWMetabolic activation, hepatic protein covalent binding, and cytotoxicity of arctigenin. ↗Chen Y et al.. Metabolic activation, hepatic protein covalent binding, and cytotoxicity of arctigenin.. Toxicol Lett. 2025. PMID:41325899.PMID 41325899 ↗Journal Toxicol LettYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41325899/
-
Observational / other LOW evidence YELLOWDecoding gout pathogenesis: target discovery and drug design through computational models. ↗Chanda HMKC et al.. Decoding gout pathogenesis: target discovery and drug design through computational models.. In Silico Pharmacol. 2025. PMID:41282962.PMID 41282962 ↗Journal In Silico PharmacolYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41282962/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Burdock Root Extract. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Burdock Root Extract
A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.